About Regenerx Biopharmaceuticals (OTCMKTS:RGRX)

RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapeutic peptide, Thymosin beta 4, for tissue and organ protection, repair, and regeneration. The company is developing RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease, or other pathology; RGN-352, an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications; and RGN-137, a topical gel for dermal wounds and reduction of scar tissue. It also evaluates the commercial development of peptide fragments and derivatives of Tß4 for potential cosmeceutical and other personal care uses. The company was formerly known as Alpha 1 Biomedicals, Inc. and changed its name to RegeneRx Biopharmaceuticals, Inc. in 2000. RegeneRx Biopharmaceuticals, Inc. was founded in 1982 and is headquartered in Rockville, Maryland.

Receive RGRX News and Ratings via Email

Sign-up to receive the latest news and ratings for RGRX and its competitors with MarketBeat's FREE daily newsletter.

News coverage about RGRX stock has trended somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies negative and positive press coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Regenerx Biopharmaceuticals earned a media sentiment score of 0.15 on Accern's scale. They also gave news coverage about the biopharmaceutical company an impact score of 46.05 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next several days.

How do I buy shares of Regenerx Biopharmaceuticals?

Shares of RGRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Regenerx Biopharmaceuticals' stock price today?

One share of RGRX stock can currently be purchased for approximately $0.20.

How big of a company is Regenerx Biopharmaceuticals?

Regenerx Biopharmaceuticals has a market capitalization of $23.09 million and generates $50,000.00 in revenue each year. Regenerx Biopharmaceuticals employs 10 workers across the globe.

MarketBeat Community Rating for Regenerx Biopharmaceuticals (RGRX)

MarketBeat's community ratings are surveys of what our community members think about Regenerx Biopharmaceuticals and other stocks. Vote "Outperform" if you believe RGRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RGRX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

1 Wall Street analysts have issued ratings and price targets for Regenerx Biopharmaceuticals in the last 12 months. Their average twelve-month price target is $1.50, suggesting that the stock has a possible upside of 650.00%. The high price target for RGRX is $1.50 and the low price target for RGRX is $1.50. There are currently 1 buy rating for the stock, resulting in a consensus rating of "Buy."